{"uri": "eng-9426360", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Research_and_development", "type": "wiki", "score": 100, "label": {"eng": "Research and development"}}, {"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer", "type": "wiki", "score": 73, "label": {"eng": "Chief executive officer"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_trial", "type": "wiki", "score": 56, "label": {"eng": "Clinical trial"}}, {"uri": "http://en.wikipedia.org/wiki/Nasdaq", "type": "wiki", "score": 47, "label": {"eng": "Nasdaq"}}, {"uri": "http://en.wikipedia.org/wiki/Marketing", "type": "wiki", "score": 47, "label": {"eng": "Marketing"}}, {"uri": "http://en.wikipedia.org/wiki/Common_stock", "type": "wiki", "score": 46, "label": {"eng": "Common stock"}}, {"uri": "http://en.wikipedia.org/wiki/Revenue", "type": "wiki", "score": 42, "label": {"eng": "Revenue"}}, {"uri": "http://en.wikipedia.org/wiki/Amortization_(accounting)", "type": "wiki", "score": 38, "label": {"eng": "Amortization (accounting)"}}, {"uri": "http://en.wikipedia.org/wiki/Fair_value", "type": "wiki", "score": 37, "label": {"eng": "Fair value"}}, {"uri": "http://en.wikipedia.org/wiki/Enzyme_inhibitor", "type": "wiki", "score": 36, "label": {"eng": "Enzyme inhibitor"}}, {"uri": "http://en.wikipedia.org/wiki/Cash_flow", "type": "wiki", "score": 36, "label": {"eng": "Cash flow"}}, {"uri": "http://en.wikipedia.org/wiki/Line_of_credit", "type": "wiki", "score": 34, "label": {"eng": "Line of credit"}}, {"uri": "http://en.wikipedia.org/wiki/Net_income", "type": "wiki", "score": 34, "label": {"eng": "Net income"}}, {"uri": "http://en.wikipedia.org/wiki/Equity_(finance)", "type": "wiki", "score": 34, "label": {"eng": "Equity (finance)"}}, {"uri": "http://en.wikipedia.org/wiki/GlobeNewswire", "type": "org", "score": 33, "label": {"eng": "GlobeNewswire"}}, {"uri": "http://en.wikipedia.org/wiki/Food_and_Drug_Administration", "type": "wiki", "score": 32, "label": {"eng": "Food and Drug Administration"}}, {"uri": "http://en.wikipedia.org/wiki/Drug_development", "type": "wiki", "score": 30, "label": {"eng": "Drug development"}}, {"uri": "http://en.wikipedia.org/wiki/Cash_and_cash_equivalents", "type": "wiki", "score": 29, "label": {"eng": "Cash and cash equivalents"}}, {"uri": "http://en.wikipedia.org/wiki/\u00c2", "type": "wiki", "score": 29, "label": {"eng": "\u00c2"}}, {"uri": "http://en.wikipedia.org/wiki/Private_Securities_Litigation_Reform_Act", "type": "wiki", "score": 28, "label": {"eng": "Private Securities Litigation Reform Act"}}, {"uri": "http://en.wikipedia.org/wiki/Biotechnology", "type": "wiki", "score": 28, "label": {"eng": "Biotechnology"}}, {"uri": "http://en.wikipedia.org/wiki/France", "type": "loc", "score": 24, "label": {"eng": "France"}, "location": {"type": "country", "label": {"eng": "France"}}}, {"uri": "http://en.wikipedia.org/wiki/United_States", "type": "loc", "score": 21, "label": {"eng": "United States"}, "location": {"type": "country", "label": {"eng": "United States"}}}, {"uri": "http://en.wikipedia.org/wiki/China", "type": "loc", "score": 17, "label": {"eng": "China"}, "location": {"type": "country", "label": {"eng": "China"}}}, {"uri": "http://en.wikipedia.org/wiki/Europe", "type": "loc", "score": 16, "label": {"eng": "Europe"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Italy", "type": "loc", "score": 10, "label": {"eng": "Italy"}, "location": {"type": "country", "label": {"eng": "Italy"}}}, {"uri": "http://en.wikipedia.org/wiki/United_Kingdom", "type": "loc", "score": 10, "label": {"eng": "United Kingdom"}, "location": {"type": "country", "label": {"eng": "United Kingdom"}}}, {"uri": "http://en.wikipedia.org/wiki/Spain", "type": "loc", "score": 10, "label": {"eng": "Spain"}, "location": {"type": "country", "label": {"eng": "Spain"}}}, {"uri": "http://en.wikipedia.org/wiki/Germany", "type": "loc", "score": 10, "label": {"eng": "Germany"}, "location": {"type": "country", "label": {"eng": "Germany"}}}, {"uri": "http://en.wikipedia.org/wiki/LinkedIn", "type": "org", "score": 9, "label": {"eng": "LinkedIn"}}, {"uri": "http://en.wikipedia.org/wiki/Business_Wire", "type": "org", "score": 7, "label": {"eng": "Business Wire"}}, {"uri": "http://en.wikipedia.org/wiki/Australia", "type": "loc", "score": 7, "label": {"eng": "Australia"}, "location": {"type": "country", "label": {"eng": "Australia"}}}, {"uri": "http://en.wikipedia.org/wiki/Beijing", "type": "loc", "score": 5, "label": {"eng": "Beijing"}, "location": {"type": "place", "label": {"eng": "Beijing"}, "country": {"type": "country", "label": {"eng": "China"}}}}], "eventDate": "2024-03-22", "totalArticleCount": 22, "title": {"eng": "GenSight Biologics Reports Full Year 2023 Consolidated Financial Results"}, "summary": {"eng": "GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its full year 2023 consolidated financial results, as approved by the Board of Directors on March 21, 2024. Audit procedures on the Company\u00e2\u0080\u0099s 2023 consolidated financial statements were completed by the Company\u00e2\u0080\u0099s statutory auditors. Fi"}, "location": null, "categories": [{"uri": "dmoz/Business/Investing", "label": "dmoz/Business/Investing", "wgt": 100}, {"uri": "dmoz/Society/Issues/Business", "label": "dmoz/Society/Issues/Business", "wgt": 100}, {"uri": "dmoz/Business/Investing/Guides", "label": "dmoz/Business/Investing/Guides", "wgt": 100}, {"uri": "news/Business", "label": "news/Business", "wgt": 96}], "articleCounts": {"eng": 22}, "sentiment": 0.3019607843137255, "wgt": 448761600, "relevance": 2}